Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Quantitative Immunoturbidimetry
Quantitative Capillary Electrophoresis
Qualitative Immunofixation Electrophoresis
Quantitative Spectrophotometry
Colorimetric Assay
Alpha, Beta, and Gamma globulins
Ganglioside Ab
MAG Ab
Protein Electrophoresis
SGPG Ab
Serum SST
Specimen Type: Serum
Container/Tube: Serum Separator Tube (SST)
Specimen Volume: 4 mL
Collection Instructions: Draw blood in a serum gel tube(s). Spin down and send 4 mL serum refrigerated in plastic vial.
2 mL
Hemolysis | Mild reject; Gross reject |
Lipemia | Mild OK; Gross reject |
Icterus | Mild OK; Gross reject |
Other | Plasma, CSF, or other body fluids. Heat-inactivated, contaminated specimens |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum SST | Refrigerated (preferred) | 7 days | |
Frozen | 30 days |
Asialo-GM1 Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GM1 Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1a Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1b Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GQ1b Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM:
Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.
Total Protein, Serum:
6.3-8.2 g/dL
Albumin:
3.75-5.01 g/dL
Alpha 1 Globulin:
0.19-0.46 g/dL
Alpha 2 Globulin:
0.48-1.05 g/dL
Beta Globulin:
0.48-1.10 g/dL
Gamma:
0.62-1.51 g/dL
Immunoglobulin A:
0 - 2 years: 2 - 126 mg/dL
3 - 4 years: 14 - 212 mg/dL
5 - 9 years: 52 - 226 mg/dL
10 - 14 years: 42 - 345 mg/dL
15 - 18 years: 60 - 349 mg/dL
19 years and older: 68 - 408 mg/dL
Immunoglobulin G:
0 - 2 years: 242 - 1108 mg/dL
3 - 4 years: 485 - 1160 mg/dL
5 - 9 years: 514 - 1672 mg/dL
10 - 14 years: 581 - 1652 mg/dL
15 - 18 years: 479 - 1433 mg/dL
19 years and older: 768 - 1632 mg/dL
Immunoglobulin M:
0 - 2 years: 21 - 215 mg/dL
3 - 4 years: 26 - 155 mg/dL
5 - 9 years: 26 - 188 mg/dL
10 - 14 years: 47 - 252 mg/dL
15 - 18 years: 26 - 232 mg/dL
19 years and older: 35-263 mg/dL
Monoclonal Protein:
Units: g/dL
Myelin Associated Glycoprotein (MAG) Antibody, IgM:
Less than 1000 TU
An elevated IgM antibody concentration greater than 999 TU against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.
TU= Titer Units
Sulfate-3-Glucuronyl Paragloboside (SGPG) Antibody, IgM:
Less than 1.00 IV
The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy with conduction block.
Sunday through Saturday
This test was developed and its perfomance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
82784 x 3
83516 x 7
84155
84165
86334
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FMNPP | Motor Neuropathy Panel | Not Provided |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
Z4539 | MAG Antibody, IgM | 17314-6 |
Z4540 | SGPG Antibody, IgM | 31666-1 |
Z4541 | Asialo-GM1 Antibodies, IgG-IgM | 44737-5 |
Z4542 | GM1 Antibodies, IgG-IgM | 63244-8 |
Z4543 | GD1a Antibodies, IgG-IgM | 48656-3 |
Z4544 | GD1b Antibodies, IgG-IgM | 26870-6 |
Z4545 | GQ1b Antibodies, IgG-IgM | 31674-5 |
Z4546 | Immunoglobulin G | 2465-3 |
Z4547 | Immunoglobulin A | 2458-8 |
Z4548 | Immunoglobulin M | 2472-9 |
Z4549 | Total Protein, Serum | 2885-2 |
Z4550 | Albumin | 1751-7 |
Z4551 | Alpha 1 Globulin | 2865-4 |
Z4552 | Alpha 2 Globulin | 2868-8 |
Z4553 | Beta Globulin | 2871-2 |
Z4554 | Gamma | 2874-6 |
Z4555 | Immunofixation | 25700-6 |
Z4556 | SPEP-IFE Interpretation | 49275-1 |
Z4557 | EER Motor Neuropathy Panel | 11526-1 |
Z6250 | Monoclonal Protein | Not Provided |
Change Type | Effective Date |
---|---|
Test Changes - Referral Fee | 2023-02-02 |
New Test | 2022-08-15 |